We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Science In Sport Plc | LSE:SIS | London | Ordinary Share | GB00BBPV5329 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.75 | 111,056 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 15.50 | 16.00 | 15.75 | 15.75 | 15.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Health & Allied Services,nec | 63.77M | -10.91M | -0.0640 | -2.46 | 26.83M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:37:43 | O | 15,887 | 15.66 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/3/2024 | 13:21 | ALNC |  Science in Sport annual revenue dips on lower trading |
| 06/3/2024 | 07:00 | UK RNS | Science in Sport PLC Trading Update |
| 05/1/2024 | 09:07 | ALNC | IN BRIEF: Science in Sport executive chair buys first million shares |
| 05/1/2024 | 07:00 | UKREG | Science in Sport PLC Director/PDMR Shareholding |
| 05/1/2024 | 07:00 | UKREG | Science in Sport PLC Notification of Major Holdings |
| 02/1/2024 | 16:42 | UKREG | Science in Sport PLC Notification of Major Holdings |
| 29/12/2023 | 11:20 | UKREG | Science in Sport PLC Issue of Equity and Total Voting Rights |
| 19/10/2023 | 11:48 | ALNC | IN BRIEF: Science in Sport CEO steps down with immediate effect |
| 19/10/2023 | 07:00 | UKREG | Science in Sport PLC Directorate Change |
| 16/10/2023 | 15:01 | ALNC | IN BRIEF: Science in Sport confirms Dan Wright as new chair |
Science In Sport (SIS) Share Charts1 Year Science In Sport Chart |
|
1 Month Science In Sport Chart |
Intraday Science In Sport Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/2/2024 | 12:50 | Science in Sport | 455 |
| 04/3/2018 | 19:06 | Man U Sponsorship | - |
| 12/1/2004 | 21:16 | On The Right Track CybIT | - |
| 12/1/2004 | 21:15 | On The Right Track | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-19 14:37:44 | 15.66 | 15,887 | 2,487.90 | O |
| 2024-04-19 14:35:59 | 15.67 | 15,882 | 2,487.92 | O |
| 2024-04-19 14:32:08 | 15.75 | 10,000 | 1,575.00 | O |
| 2024-04-19 13:21:44 | 15.50 | 32,737 | 5,074.24 | O |
| 2024-04-19 09:16:42 | 15.98 | 36,550 | 5,838.86 | O |
| Top Posts |
|---|
Posted at 20/4/2024 09:20 by Science In Sport Daily Update Science In Sport Plc is listed in the Health & Allied Services,nec sector of the London Stock Exchange with ticker SIS. The last closing price for Science In Sport was 15.75p.Science In Sport currently has 170,374,511 shares in issue. The market capitalisation of Science In Sport is £26,833,985. Science In Sport has a price to earnings ratio (PE ratio) of -2.46. This morning SIS shares opened at 15.75p |
Posted at 05/1/2024 20:04 by bozzy_s As an outsider looking in, it looks like (probably) ex-CEO exercised an option on 9.8 million shares, and immediately sold them, 9.7 million being bought by LO. Otherwise most likely would've sold them into the market and caused the price to drop. |
Posted at 07/3/2022 14:09 by km18 ...from last month...Company overview: Science in Sport encompasses departments engaged in developing, manufacturing, and marketing sports nutrition products for professional athletes and sports enthusiasts. Considering the growing importance of physical activity amid lockdowns, Science in Sport performed ahead of market expectations, after revenue grew 25%. Subsequently, EBITDA leapt to £2.2m from £1.1m in 2020, since the firm’s EV/EBITDA ratio is attractively valued at 67.6x, higher than the consumer staples EV/EBITDA ratio of 17.5x, signifying that the firm is currently outperforming its operating sector, in term of profitability, intrinsic value and potential growth. This plausible evidence is supported by the firm’s CAGR of 39.8%, above the consumer staples CAGR of 8.2%, hence Science in Sport is expected to surge in value and outperform its competitors while providing ample investment opportunities. Brief Analysis: EBITDA of £2.2m, above last year. EV/EBITDA = 67.6x, significantly above the sector benchmark. CAGR of 39.8%, substantially higher than sector threshold. Revenue of £62.7m, outperforming the previous £50.4m revenue... ...from WealthOracleAM |
Posted at 22/2/2022 13:58 by sphere25 Another big exchange gone through at 59p of 5.367m, which is about 4% of the company. Very notable exchanges as buyers attempt to arrest the decline in the downward trend by clearing sellers.It is hard to tell if this is a short term top with another leg lower (as sellers keep on coming in, feeding in shares to the market and exhaust these buyers) or whether these huge clear outs are sufficient to have cleared all major sellers to allow the price to find some steady footing. The external market influences are very fluid right now too. This type of action shows the amount of buying needed (even if to temporarily halt the downtrend) when markets get extremely bearish on these higher multiple growth shares. There are alot of shares out there where the buyers in size continue to refuse to step in the way and the down trends continue with no end in sight. SIS is in that category of higher multiple share so interested to see if the exchanges here are enough. Clearly the multiples are nowhere near the likes of where ARK shares in the US, ITM, CWR, AFC, PODP, TRST, DARK, MADE, THG etc etc etc etc... got to (and indeed still are) so one up for debate as big exchanges happen on the bullish and bearish front. Who will be right? I guess we wait and see. I would love to buy back in the 30's again (ha) but I am a greedy dreamer too. What a contrast to times back from late 2021 where we had it so good, I mean so damn good! Now it is much more difficult and defence has to be played. Beyond SIS, no notable action out there in the shares I watch to signal buyers are willing to step in the way yet to clear sellers in size. How about some big director buying post results season to send a bullish signal where investors should consider buying in too? A few things to look out for but Putin rules the roost right now. Certainly not easy to make returns at the moment! All imo DYOR |
Posted at 21/2/2022 20:43 by bareknee There's probably some value in the current share price ( 59p ) which values the company at roughly 80 million. Given the revenue for the FY was just shy of 63 million, that seems decent value.On the other hand, cash is still being burnt, partly because of the capex on the factory so more cash may be needed relatively soon, and the old adage about "Turnover is show, profit is dough" is always valid. Tough call, but I've bought back in recently. |
Posted at 11/6/2021 13:16 by bareknee Re "Hands up if you lobbed too early"Guilty as charged ! Having, for once, bought in at the right time at ~31p, I sold a third of my holding at ~60p and sold the second third at ~81p. If the price keeps rising, without any major positive news, then I see 100p+ as a total exit point. If SiS gets taken out, then my strategy will look a bit foolish ! Incidentally, Brighter Foods was bought on ~2x revenue and was turning a decent profit, though Grenade did go for a bigger premium of 4x revenue on very little profit. They're similar companies to SiS, so comparisons are valid, but, though a similar size, SiS feels a bit more niche ? The stated target here is roughly double digit EBITDA returns on revenues of ~100 million, so EBIDTA of ~10 million [n] years down the line. At 81p, we currently have a market cap of ~110 million, so, though we're not hideously overvalued, I do think we're very much on the top side of fair value. |
Posted at 10/6/2021 16:15 by sphere25 Blooming hek, it's still going up.Hands up if you lobbed too early, including quicker trades? So err...yeah :-) Haven't tried the hydration tabs (maybe they help with trading?) Oiht but did try one of the SIS Isotonic gel's a while back. It made me want to punch myself in the face....repeatedly. Yuk! Horrible taste so that needs improving. The protein shakes are good though. Anyway here is River and Mercantile highlighting how erm.. "cheap" SIS is: "The most significant contributor to performance in the month was Science in Sport, our largest holding, which finished the month 19% higher. It appears that corporate activity in the sector may be behind the re-rating with The Hut Group acquiring Brighter Foods and Mondelez acquiring Grenade (a reported 4x EV/Sales which compares nicely to SIS’ multiple of sales of less than 2x). " All imo DYOR |
Posted at 09/6/2021 18:08 by oiht I buy SIS hydration tabs, I've tried other brands but somehow I always come back to SIS despite the premium price. I am a holder of the shares though, so I readily concede that I am not impartial. I took up my full entitlement of rights issue in 2107 and now, for the first time in years, I am actually 'in the money' by fourteen quid. Yeeha!!Only today I ordered three more tubes of berry flavour - that should hit the bottom line any day :-o |
Posted at 17/3/2021 15:30 by sphere25 Further to the previous post, this is a case in point on valuations and perceptions of valuations.If somebody did a survey to look at those results and ask the question on whether the shares represented value, would the majority of participants say it represented value? Personally speaking, I wouldn't put this in the value basket. However, in these markets, premiums are willing to be paid and those who ride the waves regardless of valuations have clearly been doing the best. I have been lobbing here because it has gone through what I thought was a bullish target price but the market is more than happy to continue bidding the shares up. When I lob, prices usually keep going higher - that's my new party trick and the market. On the flip side, why could the market be willing to pay a premium valuation here? Naturally there is the resilient revenue performance which the market believes is the foundation for further growth as lockdowns ease/end. There is also margin improvement and the growth in online sales has been good. The online growth has also accelerated into the new financial year and the market clearly believes the online side will be more resilient even when high streets open up. There must also be a belief in the international growth, particularly the likes of the US where SIS have alighted to 33% revenue growth and significantly reduced cash burn gain more traction. Furthermore, the market opportunity is clearly growing and there must be alot of pent up demand from folk who want to get out and exercise more freely and perhaps more who are being advised to get out and exercise more on health grounds from being inside all the time. Clearly people want to get out and live their lives more so perhaps there will be greater focus on the health side as a result of the pandemic. Headlines like the one today that Brits will go on a £50 billion spending spree have been adding to the optimism in all markets. Naturally, there is a divide here with lower income folk not being in as strong a position to save, or indeed not save altogether, with so much commentary on savings increasing. SIS have also delayed product launches so some of that must be feeding into the valuation too. I have tried numerous PHD products and they are good. They are clean, taste good and have worked well for me. The range of flavours is extensive with the likes of chocolate mint though haven't tried the Raspberry and White choc or Cherry Bakewell! The pricing can be more premium, but offers are regular, so you can pick them up buy one get one free at times - Holland and Barrett do the offers. Clearly it is all about execution now and SIS is priced for solid execution. Even though many can argue the sales metrics are cheap relative to wider markets, there cannot be slip ups in my humble opinion. Happy to keep an eye on it though do tend to lose interest in the ones that have hit targets beyond quick trades. All imo DYOR |
Posted at 15/3/2021 12:39 by sphere25 Price currently 52p.Finally gone through the price target and gap close on the chart. It looks like the offer has been pulled ahead of the results here by the sellers who were holding this back for a while. It is not unknown for this to happen. They will reassess on the results due this week on the 17th March. Happy to have ridden this one along with a nice market that has afforded everyone (particularly short term folk) the luxury of giving shares more of a chance. If the market wasn't as bullish or less stable, then the approach would clearly be different with less leeway given, and indeed immediate cuts for anything that didn't work if it was very volatile. Part of the interest with SIS was the statements taking a more bullish tone (sometimes indicative of a major turn with recovery potential) but also the wider premium ratings that the market has been willing to pay, so despite understandable skepticism by some posters on SIS (as well as my usual ramblings on overvalued parts of the market), it almost doesn't matter about our perception of a valuation at times. What can matter more is our perception of the market's perception of the value, which is all related to the level of bullish spirits. Working on operating metrics of sales with the likes of SIS isn't really my thing, but clearly there are arguments both ways for value here and the market has been happy to bid it up i.e. very bullish spirits and a belief that the future has changed for the better for SIS. Happy to ride these waves in many companies, and selling along the way, but not one to get attached to any company. Hard to say how the market will react to the update here on Wednesday. With the more premium type of rating, the outlook will have to be a positively solid in line with expectations statement at worst imo. Clearly different for longer term folk. Onwards! All imo DYOR |
Posted at 11/2/2021 11:44 by sphere25 Recent note:"Liberum: SIS shares remain cheap Science in Sport (SIS) has put the building blocks in place to deliver growth and its shares remain cheap, says Liberum. Analyst Adam Tomlinson retained his ‘buy’ recommendation and target price of 80p on the sports drinks company, which closed up 2.3%, or 1p, at 45p yesterday. After a ‘resilient full year 2020’ and a positive capital markets presentation, ‘the building blocks are now in place for SIS to deliver long-term profitable growth’, Tomlinson said. ‘Management Tomlinson added that margin expansion will be supported by ‘supply chain consolidation and leveraging the well-invested cost base’ and that the shares remain cheap on a current year 2021 embedded value/sales [multiple] of 1 times versus peers on 2 times." Again as per posts today on broker calls, it's all too bullish. Also don't like it when we have to talk about valuations in operating metrics based on sales rather profits and cashflow so perhaps pushing the boat out here more than usual. The thing is though, that is the kind of market we are in! The valuations aren't giving any guide to future performance and what appears to be expensive has continued to go higher and become more expensive. Folk will have noted alot of my terrible selling based on what I have thought was a fairer value after realising good gains in alot of highlighted shares, except the near majority of those have carried on going higher so it really has been one of those markets that continues to surprise. Furthermore, the US appears even more bullish than the analyst above. If SIS was offered to US investors, they'd look at that operating metric of 1 and double it and more in a flash so you'd probably end up smashing through the 80p target in one fair swoop. The path of least resistance continues to be up regardless of views on valuation. Looks like we've got stuck here atm but more bullish updates and the re-rates in the likes of SIS will continue. If something changes for the worse at some point in the future, then clearly have to give back some of the gains. All imo DYOR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
